The strategic degradation of BCR-ABL through Beclin-1 mediated autophagy suggests a novel therapeutic pathway to mitigate TKI resistance, a prevalent challenge in CML treatment. Here, BECN1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.